Patents Issued in October 9, 2018
-
Patent number: 10092618Abstract: New Lactococcus lactis strains, NRRL B-50571 and NRRL B-50572, and a bacterial preparation containing the same, have the ability to produce bioactive peptides that reduce blood pressure, lower LDL-cholesterol (bad cholesterol) and present antioxidant properties for better cardiovascular health. These biologically active peptides may be produced within the food for the production of a food product, such as a functional food, or they may be produced from protein sources and subsequently added to a food as part of the formulation or as part of a food supplement or a pharmaceutical preparation.Type: GrantFiled: November 18, 2016Date of Patent: October 9, 2018Assignees: Centro De Investigación En Alimentacion Y Desarrollo, A.C. (CIAD)Inventors: Belinda Vallejo Galland, Aarón Fernando González Córdova, Jóse Carlos Rodríguez Figueroa
-
Patent number: 10092619Abstract: New Lactococcus lactis strains, NRRL B-50571 and NRRL B-50572, and a bacterial preparation containing the same, have the ability to produce bioactive peptides that reduce blood pressure, lower LDL-cholesterol (bad cholesterol) and present antioxidant properties for better cardiovascular health. These biologically active peptides may be produced within the food for the production of a food product, such as a functional food, or they may be produced from protein sources and subsequently added to a food as part of the formulation or as part of a food supplement or a pharmaceutical preparation.Type: GrantFiled: November 21, 2016Date of Patent: October 9, 2018Assignees: Centro De Investigación En Alimentacion Y Desarrollo, A.C. (CIAD)Inventors: Belinda Vallejo Galland, Aarón Fernando González Córdova, Jóse Carlos Rodríguez Figueroa
-
Patent number: 10092620Abstract: The present invention provides cyclic compounds that are useful in preventing or treating atherosclerosis or related disorders. The invention also provides therapeutic methods for treating or preventing various diseases or disorders associated with or mediated by atherosclerosis. Further provided in the invention are methods of screening for anti-atherosclerotic cyclic peptides with improved properties.Type: GrantFiled: April 2, 2014Date of Patent: October 9, 2018Assignee: The Scripps Research InstituteInventors: M. Reza Ghadiri, Luke J. Leman, Yannan Zhao, Bruce E. Maryanoff
-
Patent number: 10092621Abstract: Enteral Feeding Intolerance (EFI) can be efficaciously treated by administration of therapeutically effective doses of ulimorelin every 8 hours (three times a day). Therapeutic benefit can be obtained from single and consecutive daily dosing, including for periods of up to a week or longer.Type: GrantFiled: November 11, 2015Date of Patent: October 9, 2018Assignee: Lyric Pharmaceuticals Inc.Inventors: David Wurtman, Joyce James, M. Scott Harris
-
Patent number: 10092622Abstract: The present invention is directed to novel antifungal glycopeptide compounds and salts thereof produced by a strain of Burkholderia contaminans useful for preventing or treating fungal infection or disease in animals and plants and the bacterial strain that produces the compounds.Type: GrantFiled: July 22, 2015Date of Patent: October 9, 2018Assignee: MISSISSIPPI STATE UNIVERSITYInventors: Shien Lu, James L. Smith, Frank Austin, Ganyu Gu
-
Patent number: 10092623Abstract: The present invention provides therapeutic and prophylactic compositions for use in treating and preventing disorders involved epithelial cell apoptosis, such as gastrointestinal disorders (e.g., inflammatory bowel disease, Crohn's disease or ulcerative colitis) in a subject, such as a human patient.Type: GrantFiled: May 26, 2017Date of Patent: October 9, 2018Assignee: VANDERBILT UNIVERSITYInventors: D. Brent Polk, Fang Yan
-
Patent number: 10092624Abstract: Provided are peptides that can inhibit collagen synthesis, processing and/or secretion. In some aspects, the therapeutic peptides may be used to treat a cancer such as, e.g., a pancreatic cancer or a glioblastoma.Type: GrantFiled: April 22, 2016Date of Patent: October 9, 2018Assignees: MUSC Foundation for Research Development, University of South CarolinaInventors: Robert G. Gourdie, Edie C. Goldsmith, L. Jane Jourdan, Joshua Matthew Rhett, Michael J. Yost
-
Patent number: 10092625Abstract: Heat-treated liquid enteral nutritional composition with a low monovalent metal ion content are provided that contain micellar casein and optionally caseinate, and in which the total amount of monovalent metal ions is less than 25 mg/g of protein. Also, heat-treated liquid enteral nutritional compositions are disclosed comprising 10 to 20 g of protein per 100 ml of the composition, in which all or a major part of said protein comprises micellar casein. Also, a method is disclosed for producing the composition according to the invention, comprising a step wherein an aqueous protein solution in which all or a major part of said protein comprises micellar casein, is subjected to an evaporation step.Type: GrantFiled: October 17, 2016Date of Patent: October 9, 2018Assignee: N.V. NutriciaInventors: Marcel Minor, Suzanne Van Steenis, Hilde Ruis
-
Patent number: 10092626Abstract: As microbial drug-resistance increases, there is a critical need for new classes of compounds to combat infectious diseases. The Ixodes scapularis tick antifreeze glycoprotein, IAFGP, functions as an anti-infective agent against diverse bacteria including methicillin-resistant Staphylococcus aureus. Recombinant IAFGP and a peptide, PI, described herein and derived from this protein, bind to microbes and alter biofilm formation. Transgenic iafgp-expressing flies and mice challenged with bacteria, as well as wild-type animals administered IAFGP or PI, were resistant to infection, septic shock, or biofilm development on implanted biomaterials. Antifreeze protein controls bacterial infection and present new therapeutic strategies to counter pathogens.Type: GrantFiled: December 17, 2014Date of Patent: October 9, 2018Assignees: Yale University, Howard Hughes Medical InstituteInventors: Erol Fikrig, Martin Heisig, Nabil Abraham, Girish Neelakanta
-
Patent number: 10092627Abstract: Methods and compositions for rejuvenating skeletal muscle stem cells are disclosed.Type: GrantFiled: April 8, 2014Date of Patent: October 9, 2018Assignees: President and Fellows of Harvard College, The Brigham and Womens's Hospital, Inc.Inventors: Amy J. Wagers, Richard T. Lee
-
Patent number: 10092628Abstract: This document provides methods and materials for treating cardiovascular and/or renal diseases. For example, AAV9 vectors designed to express natriuretic polypeptides, nucleic acid molecules encoding natriuretic polypeptides, methods for making AAV9 vectors, and methods for using such vectors or molecules to treat cardiovascular and/or renal diseases are provided.Type: GrantFiled: April 30, 2018Date of Patent: October 9, 2018Assignee: Mayo Foundation for Medical Education and ResearchInventors: Yasuhiro Ikeda, Stephen James Russell, Alessandro Cataliotti, John C. Burnett, Jr., Jason M. Tonne
-
Patent number: 10092630Abstract: The present system is directed in several embodiments to a method of administration of a therapeutic composition for treatment of Anorexia Nervosa, safely and without significantly affecting the blood glucose or blood insulin levels of the patient. The method includes administering one or more therapeutic compositions comprising an effective amount of insulin directly to the subject patient's CNS, with no to minimal systemic exposure. Preferably, this method comprises administration of an effective amount of insulin to the upper third of a patient's nasal cavity, thereby bypassing the patient's blood-brain barrier and delivering the therapeutic composition directly to the patient's central nervous system.Type: GrantFiled: November 1, 2016Date of Patent: October 9, 2018Assignee: HealthPartners InstituteInventor: William H. Frey, II
-
Patent number: 10092631Abstract: A headache can be treated more effectively by co-administration of a botulinum toxin and a triptan drug to a patient and/or the effectiveness of a triptan medication can be increased. The botulinum toxin can be botulinum toxin type A and the botulinum toxin can be administered to or to the vicinity of where a patient experiences or is predisposed to experience pain or a headache.Type: GrantFiled: January 23, 2017Date of Patent: October 9, 2018Assignee: Allergan, Inc.Inventors: Catherine C. Turkel, Mitchell F. Brin
-
Patent number: 10092632Abstract: Vaccines and methods of inoculation for conferring immunity to Cryptococcus infection are disclosed. Strains of Cryptococcus fungi, including Cryptococcus neoformans and Cryptococcus gattii, can be administered to a human or animal subject via inhalation. Cryptococcus fungi that can be used to confer immunity can comprise one or more mutations in genes that contribute to chitosan production, such as genes encoding a chitin deacetylase (cda), a chitin synthase (chs) and/or a regulator of chitin synthase (csr). Inhalation administration of heat-killed Cryptococcus harboring deletions in cda1, cda2 and cda3 genes can confer immunity. In a murine model system, inhalation administration of Cryptococcus neoformans harboring deletions in cda1, cda2 and cda3 genes conferred immunity against subsequent exposure to wild type Cryptococcus neoformans in 100% of test animals. Inhalation administration of heat-killed Cryptococcus grown under conditions leading to reduced chitosan production can also confer immunity.Type: GrantFiled: May 14, 2015Date of Patent: October 9, 2018Assignee: Washington UniversityInventors: Jennifer Lodge, Woei Lam, Rajendra Upadhya
-
Patent number: 10092633Abstract: The invention relates to newly identified peptides of that are capable of inducing tolerance to cow's milk, especially to ?-lactoglobulin. The peptides may be administered to mammals, especially to young infants who are at risk of allergy to cow's milk proteins, to induce oral tolerance to cow's milk; they may also be administered to children or adults who are allergic to cow's milk to allow “desensitization” towards the allergenic milk proteins, especially ?-lactoglobulin, to occur. The peptides may also be used to induce tolerance to goat's and buffalo's milk proteins, especially ?-lactoglobulin. The peptides are capable of modulating the mammalian immune response to allergens.Type: GrantFiled: December 16, 2013Date of Patent: October 9, 2018Assignee: Nestec S.A.Inventors: Carine Blanchard, Sophie Nutten, Alexandre Panchaud
-
Patent number: 10092634Abstract: Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the UBE2T that elicit CTLs are provided. Isolated antigen-presenting cells with CTL inducibility and CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing such epitope peptides derived from UBE2T or polynucleotides encoding the polypeptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or the prevention of a postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the epitope peptides derived from UBE2T, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.Type: GrantFiled: September 9, 2013Date of Patent: October 9, 2018Assignee: ONCOTHERAPY SCIENCE, INC.Inventors: Takuya Tsunoda, Ryuji Osawa, Sachiko Yoshimura, Tomohisa Watanabe
-
Patent number: 10092635Abstract: The present invention provides a therapeutic agent comprising an antibody-recognition epitope (ARE) covalently bound to a tumor cell, wherein the ARE is bound to an antibody that is specific for the ARE, to form a tumor cell:ARE:antibody complex, and kits and methods of using these tumor cell:ARE:antibody complexes.Type: GrantFiled: January 30, 2014Date of Patent: October 9, 2018Assignee: University of Iowa Research FoundationInventors: Tony Vanden Bush, Gail Bishop
-
Patent number: 10092636Abstract: The present disclosure provides (a) vectors comprising a multi-antigen construct encoding two, three, or more immunogenic PAA polypeptides; (b) compositions comprising the vectors, (c) methods relating to uses of the vectors and compositions for eliciting an immune response or for treating prostate cancers.Type: GrantFiled: May 4, 2016Date of Patent: October 9, 2018Assignee: Pfizer Inc.Inventor: Joseph John Binder
-
Patent number: 10092637Abstract: Described herein are dengue virus E-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes associated with immune enhancement. The disclosed dengue virus E-glycoproteins optionally further include mutations that introduce a strong CD4 T cell epitope. The disclosed E-glycoprotein polypeptides, or nucleic acid molecules encoding the polypeptides, can be used, for example, in monovalent or tetravalent vaccines against dengue virus.Type: GrantFiled: September 12, 2016Date of Patent: October 9, 2018Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Gwong-Jen J. Chang, Wayne D. Crill, Holly R. Hughes, Brent S. Davis
-
Patent number: 10092638Abstract: The present invention relates, in general, to an HIV-1 vaccine and, in particular, to a B cell lineage-based vaccination protocol.Type: GrantFiled: October 3, 2012Date of Patent: October 9, 2018Assignees: DUKE UNIVERSITY, CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Barton F. Haynes, Garnett Kelsoe, Stephen Harrison, Thomas B. Kepler
-
Patent number: 10092639Abstract: Disclosed are methods for preparing a vaccine against infection by infectious bronchitis virus (IBV). The methods typically include passing a heterogeneous attenuated population of IBV in chicken embryonic kidney cells, and optionally may include further passaging the heterogeneous attenuated population of IBV in embryonated chicken eggs (ECE) in order to obtain passaged attenuated population of IBV. Also disclosed are passaged attenuated populations of IBV in which the populations display a desired degree of homogeneity. Also disclosed are vaccines comprising the passaged attenuated populations of IBV and methods of vaccination comprising administering the disclosed vaccines.Type: GrantFiled: September 13, 2017Date of Patent: October 9, 2018Assignee: Auburn UniversityInventor: Haroldo E. Toro
-
Patent number: 10092640Abstract: The invention provides a stable immunogenic composition for prevention and prophylaxis of infections caused by rota virus, poliomyelitis virus, Haemophilius influenza, Hepatitis B, Corynebacterium diphtheriae, Clostridium tetani, Bordatella pertusis (acellular) in a single combined vaccine. The invention also provides for a bivalent immunogenic composition against rota virus and polio virus. The process of making such compositions of the multivalent antigens are also disclosed. The present invention also relates to the production and use of such vaccines for prophylaxis against the infections mentioned above.Type: GrantFiled: January 3, 2012Date of Patent: October 9, 2018Assignee: Bharat Biotech International LimitedInventors: Gopinathan Kuppuswamy, Vijayanand Thiagarajan
-
Patent number: 10092641Abstract: Methods and compositions for delivering antigens to the lymphatic system in doses that desensitize patients to future exposure to antigens have been developed. Rapid desensitization is achieved by introducing small quantities of antigen into the lymphatic system. In preferred embodiments, the compositions are administered to yield therapeutically effective levels of antigen within the lymph, where macrophages reside in the greatest concentration, by intradermal administration, using for example, microneedles or micro articles, oral administration, using for example, enteric coated capsules or tablets, or autologous transfusion. In some embodiments, the methods and compositions for delivering antigens orally achieve uptake by the Peyer's patches of the small intestines.Type: GrantFiled: April 6, 2017Date of Patent: October 9, 2018Assignee: Perosphere Technologies Inc.Inventors: Bryan E. Laulicht, Sasha H. Bakhru, Solomon S. Steiner, Edith Mathiowitz
-
Patent number: 10092642Abstract: The present invention aims at providing a mucosal vaccine composition that can be administered to an intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane, respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane, gastric mucous membrane, enteric mucous membrane, or rectal mucous membrane, that is useful as a prophylactic or therapeutic agent for infectious diseases or cancers, and is capable of safely and effectively inducing the systemic immune response and mucosal immune response.Type: GrantFiled: October 2, 2014Date of Patent: October 9, 2018Assignee: NITTO DENKO CORPORATIONInventors: Masahiro Fukasaka, Mitsuhiko Hori, Katsuyuki Okubo, Daisuke Asari, Arimichi Okazaki, Eiji Kiyotoh, Kyohei Matsushita
-
Patent number: 10092643Abstract: Provided is use of a sphingosine compound, or a derivative of a sphingosine compound, in the manufacture of a vaccine effective in the treatment and prevention of an infectious disease and treatment and/or prevention of an autoimmune disease. Also provided is use of a sphingosine compound, or a derivative of a sphingosine compound, in the manufacture of an immunomodulation medicament effective in the prevention of infectious disease and treatment and/or prevention of an autoimmune disease.Type: GrantFiled: June 30, 2006Date of Patent: October 9, 2018Inventor: Marc Creus
-
Patent number: 10092644Abstract: Disclosed is the use of fluorinated cyclic dinucleotides and pharmaceutically acceptable salts thereof as an adjuvant for the preparation of an oral vaccine. Further disclosed is the use of fluorinated cyclic dinucleotides and pharmaceutically acceptable salts thereof for enhancing the immune response to an orally administered vaccine.Type: GrantFiled: November 18, 2014Date of Patent: October 9, 2018Assignees: Brock University, National Research Council of CanadaInventors: Hongbin Yan, Wangxue Chen, Rhonda Kuo Lee
-
Patent number: 10092645Abstract: This application provides a method of treating cancer in a patient comprising administering at least one dose of radiation therapy and at least one PD-1 and/or PD-L1 antagonist, wherein at least one PD-1 and/or PD-L1 antagonist is administered on the same day as a dose of radiation therapy or up to and including 4 days later.Type: GrantFiled: June 16, 2015Date of Patent: October 9, 2018Assignee: MedImmune LimitedInventors: Ross Stewart, Michelle Morrow, Robert Wilkinson, Edmund Poon, Simon Dovedi, Tim Illidge
-
Patent number: 10092646Abstract: This disclosure describes, in one aspect, a composition that includes a ?-glucan component and an antibody component that specifically binds to the ?-glucan. In another aspect, this disclosure describes a method of increasing a subject's response to ?-glucan immunotherapy. Generally, the method includes identifying the subject as a low binder of ?-glucan and administering to the subject a composition that comprises a ?-glucan moiety conjugated to the therapeutic antibody. In some cases, the therapeutic antibody can be an anti-tumor antibody.Type: GrantFiled: March 14, 2013Date of Patent: October 9, 2018Assignee: Biothera, Inc.Inventors: William J. Grossman, Mary A. Antonysamy, Richard M. Walsh, Mariana I. Nelson, Nandita Bose, Michael E. Danielson, Kyle S. Michel
-
Patent number: 10092647Abstract: The present invention relates to a composition which includes antibodies against one or more specified virus, bacteria and/or pathogen for use to improve dog health, wherein the composition is administered before 24 hours of age of the dog or between 24 hours and up to 90 days of age of the dog.Type: GrantFiled: July 9, 2014Date of Patent: October 9, 2018Assignee: Mars, IncorporatedInventors: Alexandre Feugier, Sylvie Chastant, Hanna Mila, Aurelien Grellet
-
Patent number: 10092648Abstract: GLP-2 analogs are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an increased small intestine/colon and stomach/colon selectivity. More particularly, preferred GLP-2 analogs disclosed herein comprise substitutions at one or more of positions 11, 16, 20, 24 and/or 28 of the wild-type GLP-2 sequence, optionally in combination with further substitutions at position 2 and one or more of positions 3, 5, 7, and 10, and/or a deletion of one or more of amino acids 31 to 33 and/or the addition of a N-terminal or C-terminal stabilizing peptide sequence. The analogs are particularly useful for the prophylaxis or treatment of stomach and bowel-related disorders and for ameliorating side effects of chemotherapy.Type: GrantFiled: February 4, 2014Date of Patent: October 9, 2018Assignee: Zealand Pharma A/SInventors: Bjarne Due Larsen, Yvette Miata Petersen
-
Patent number: 10092649Abstract: The application discloses nucleoside derivatives of Formula I as inhibitors of Influenza RNA replication. In particular, the application discloses the use of purine and pyrimidine nucleoside derivatives of Formula I as inhibitors of Influenza RNA replication and pharmaceutical compositions containing such compounds.Type: GrantFiled: June 20, 2016Date of Patent: October 9, 2018Assignee: Riboscience LLCInventors: Mark Smith, Klaus G. Klumpp
-
Patent number: 10092650Abstract: A guided bone regeneration material is disclosed. The guided bone regeneration material includes biodegradable fibers produced by an electrospinning method. The biodegradable fibers produced by the method include a silicon-releasing calcium carbonate and a biodegradable polymer. The silicon-releasing calcium carbonate is a composite of siloxane and calcium carbonate of vaterite phase. The biodegradable fibers may be coated with apatite. When the guided bone regeneration material is immersed in a neutral aqueous solution, silicon species ions are eluted from the calcium carbonate. The guided bone regeneration material excels in bone reconstruction ability.Type: GrantFiled: May 5, 2014Date of Patent: October 9, 2018Assignees: National University Corporation, Nagoya Institute of Technology, Yabashi Industries Co., LTD, Yamahachi Dental Mfg., Co, Orthorebirth Co. Ltd.Inventors: Toshihiro Kasuga, Yoshio Ota, Takashi Wakita
-
Patent number: 10092651Abstract: Provided is a fast dissolving film composition comprising a medically active component as an active ingredient, in which the bitter taste of the active ingredient is masked and the fast dissolving film composition has a high content of 50% or higher. More particularly, provided is a pharmaceutical composition which comprises sildenafil or pharmaceutically acceptable salts thereof as an active ingredient, and which comprises a combination of a specific bitter taste masking agent to achieve masking of a bitter taste. Further, provided is a fast dissolving film composition which comprises a combination of a specific plasticizer to mask a bitter taste, and in which the physical properties of the high-content film are excellent.Type: GrantFiled: February 28, 2013Date of Patent: October 9, 2018Assignee: SEOUL PHARMA CO., LTD.Inventors: Hyun Jun Jeong, Ik Hyeon Chang, Dal Geun Kim, Jin Hoo Lee, Jin Hee Um, Hyun Soo Kim, Kyung Tae Jung, Kyu Jeong Yeon, Jin Gyu Park
-
Patent number: 10092652Abstract: The present invention relates to a sustained release medical composition comprising an active pharmaceutical ingredient and a geopolymeric binder. Preferably the active pharmaceutical ingredient is combined with the geopolymeric binder during the formation of that binder.Type: GrantFiled: November 8, 2016Date of Patent: October 9, 2018Assignee: Emplicure ABInventor: Hakan Engqvist
-
Patent number: 10092653Abstract: The present disclosure is directed to a class of fluorinated copolymers, such as PTFE copolymers, that can be dissolved in low toxicity solvents, such as Class III Solvents, and that enable the creation of stable water-in-solvent emulsions comprising the fluorinated copolymers dissolved in a low toxicity solvents and a hydrophilic agent (e.g., a therapeutic agent) dissolved in an aqueous solvent, such as water or saline.Type: GrantFiled: September 12, 2013Date of Patent: October 9, 2018Assignee: W. L. Gore & Associates, Inc.Inventors: Robert L. Cleek, Edward H. Cully, Paul D. Drumheller, Theresa A. Holland
-
Patent number: 10092654Abstract: A composition includes a plurality of coacervate micro and/or nanodroplets of oxidized alginate and a methacrylated gelatin.Type: GrantFiled: July 9, 2015Date of Patent: October 9, 2018Assignee: Case Western Reserve UniversityInventors: Eben Alsberg, Oju Jeon, David Wolfson
-
Patent number: 10092655Abstract: The invention provides a cationic lipid capable of achieving higher intracellular delivery efficiency than conventional cationic lipids, when used as a lipid membrane structure which is a carrier for delivering functional nucleic acid. The cationic lipid is represented by the formula (1): wherein each symbol is as defined herein.Type: GrantFiled: August 7, 2015Date of Patent: October 9, 2018Assignees: NOF CORPORATION, NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITYInventors: Shota Sasaki, Masaki Ota, Kazuhiro Kubo, Hideyoshi Harashima, Hidetaka Akita, Hiroto Hatakeyama, Yuki Noguchi, Kota Tange, Yuta Nakai, Nayuta Shimizu
-
Patent number: 10092656Abstract: Provided herein (among other things) are protease inhibitor compounds having enhanced features, along with methods for administering such compounds. For example, the subject compounds can be administered without concomitant administration of a CYP3A4 inhibitor, have increased therapeutic index and/or increased potency, and are low-resistance inducing in nature.Type: GrantFiled: August 4, 2016Date of Patent: October 9, 2018Assignee: Nektar TherapeuticsInventors: C. Simone Jude-Fishburn, Laurie A. VanderVeen, Timothy A. Riley
-
Patent number: 10092657Abstract: Described herein are compositions that include isolated opsonized soluble ?-glucan, methods of making those compositions and methods of using those compositions.Type: GrantFiled: June 1, 2012Date of Patent: October 9, 2018Assignee: Biothera, Inc.Inventors: Nandita Bose, Anissa S. H. Chan
-
Patent number: 10092658Abstract: A transdermal delivery system of drug and a method of preparing the same are provided. More specifically, the invention can be a transdermal delivery system applied for various protein drugs such as vaccines and chemical drugs, because the drug delivery system has a biocompatibility, biodegradation property, transdermal delivery property, the safety of human body, maximum activity of protein drugs, good bio-conjugation efficiency and a long-term efficacy, a method of preparing the same and its use.Type: GrantFiled: February 7, 2013Date of Patent: October 9, 2018Assignee: PHI BIOMED CO., LTD.Inventors: Sei Kwang Hahn, Eung-Sam Kim, Jeonga Yang, Hyemin Kim, Kwan Yong Choi, Ji Hye Shin, Jung-Hee Kwon
-
Patent number: 10092659Abstract: The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumors expressing HER2, wherein the human solid tumor expressing HER2 is endometrial cancer, in particular uterine serous carcinoma (USC). In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of endometrial cancer, notably USC, with HER2 IHC 2? or 1+ and HER2 FISH negative tumor tissue status.Type: GrantFiled: July 21, 2016Date of Patent: October 9, 2018Assignees: Synthon Biopharmaceuticals B.V., Yale UniversityInventors: Alessandro Davide Santin, Peter Johannes Goedings
-
Patent number: 10092660Abstract: The invention relates to solid compositions that may be suitable for administering a therapeutic agent to a subject. The invention also relates to methods of making such solid compositions. The invention further relates to methods of treating a disease, condition, or disorder by administering to a subject such solid compositions.Type: GrantFiled: April 25, 2012Date of Patent: October 9, 2018Assignee: STC.UNMInventors: Hugh Smyth, Ibrahim M. El-Sherbiny
-
Patent number: 10092661Abstract: In the present invention, a method of producing stable bare colloidal gold nanoparticles is disclosed. The nanoparticles can subsequently be subjected to partial or full surface modification. The method comprises preparation of colloidal gold nanoparticles in a liquid by employing a top-down nanofabrication method using bulk gold as a source material. The surface modification of these nanoparticles is carried out by adding one or multiple types of ligands each containing functional groups which exhibit affinity for gold nanoparticle surfaces to produce the conjugates. Because of the high efficiency and excellent stability of the nanoparticles produced by this method, the fabricated gold nanoparticle conjugates can have surface coverage with functional ligands which can be tuned to be any percent value between 0 and 100%.Type: GrantFiled: February 24, 2014Date of Patent: October 9, 2018Assignee: IMRA America, Inc.Inventors: Wei Qian, Makoto Murakami, Yuki Ichikawa, Yong Che
-
Patent number: 10092662Abstract: This invention relates to biotechnology, more particularly, to water-soluble polymeric delivery systems for the imaging, evaluation and/or treatment of rheumatoid arthritis and other inflammatory diseases. Using modern MR imaging techniques, the specific accumulation of macromolecules in arthritic joints in adjuvant-induced arthritis in rats is demonstrated. The strong correlation between the uptake and retention of the MR contrast agent labeled polymer with histopathological features of inflammation and local tissue damage demonstrates the practical applications of the macromolecular delivery system of the invention.Type: GrantFiled: March 30, 2005Date of Patent: October 9, 2018Assignee: University of Utah Research FoundationInventors: Dong Wang, Jindrich Kopecek, Scott C. Miller, Pavla Kopeckova
-
Patent number: 10092663Abstract: Polymers are described herein comprising: a reaction product of a prepolymer solution including at least one macromer, at least one flexomer, and at least one visualization agent. Methods of making and using these polymers are also described.Type: GrantFiled: April 3, 2015Date of Patent: October 9, 2018Assignee: Terumo CorporationInventors: Michael Constant, Gregory M. Cruise, Samuel Chen
-
Patent number: 10092664Abstract: Provided is a decontamination cover to be applied over an object to be decontaminated. The decontamination cover includes a sheet-like body formed from a pliable material, and includes an outward-facing surface that is substantially opaque to UVC light and an inward-facing surface that is to be arranged opposite a surface of the object to be decontaminated. A plurality of UVC sources are exposed at the inward-facing surface, and a plurality of spacers are arranged among the UVC sources to maintain a suitable separation between the UVC sources and the surface of the object to be decontaminated. This suitable separation promotes complete coverage of the surface with UVC light emitted by the UVC sources.Type: GrantFiled: July 14, 2016Date of Patent: October 9, 2018Assignee: Diversey, Inc.Inventor: Roderick M. Dayton
-
Patent number: 10092665Abstract: UV hard-surface disinfection system that is able to disinfect the hard surfaces in a room, while minimizing missed areas due to shadows by providing multiple UV light towers that can be placed in several areas of a room such that shadowed areas are eliminated and that can be transported by a cart that is low to the ground such that the towers may be loaded and unloaded easily by a single operator. The system is able to be controlled remotely, such that during activation of the system, no operator is present, and to automatically cut power to all towers in the event that a person enters the room.Type: GrantFiled: September 8, 2017Date of Patent: October 9, 2018Assignee: Surfacide, LLCInventors: Waldemar John Lyslo, Mark Howard Schwartz, Stephen Boyd Pettis
-
Patent number: 10092666Abstract: An air filter unit for removing contaminations from air is disclosed. The air filter unit includes an airflow generating device configured to generate and direct at least one airflow from an air inlet to an air outlet, a filter disposed between the air inlet and the air outlet and including at least one filter layer for removing contaminations from the at least one airflow, a heater disposed upstream of the filter and configured to heat the at least one airflow directed towards the filter, an ejection device disposed upstream of the filter and configured to inject a sterilizing agent into the at least one airflow directed towards the filter, and a duct interposed between the air inlet and the filter and configured to feed the at least one airflow to the filter. The duct includes a volute-like outlet portion, and the ejection device is arranged in the duct.Type: GrantFiled: December 2, 2015Date of Patent: October 9, 2018Assignee: SIDEL PARTICIPATION S.A.S.Inventors: Pierluigi Quagliarella, Rossana Borgese
-
Patent number: 10092667Abstract: The present invention relates to a method for sterilizing an article inside a sealed container by placing a polyoxymethylene melt formable co-polymer fiber that has been irradiated between about 1 and 200 kGy and then heated at from about 20° C. to about 90° C. for a selected period of time.Type: GrantFiled: November 7, 2013Date of Patent: October 9, 2018Assignee: Brighton Development, LLCInventors: Joel Lawson Williams, Lois A. Jones, Paul M. Vernon, Jr.
-
Patent number: 10092668Abstract: A fogging device for disinfecting an enclosed area with an atomized disinfectant fluid may include a housing, and an atomizing disinfectant generator carried by the housing and including a disinfectant fluid reservoir, a compressor coupled to the disinfectant fluid reservoir, and an atomizing nozzle in fluid communication with the disinfectant fluid reservoir. A first processor may be carried by the housing and coupled to the compressor and configured to perform a treatment cycle during which the compressor is operated to dispense atomized disinfectant fluid from the disinfectant fluid reservoir into the enclosed area via the atomizing nozzle. The treatment cycle may include a saturation phase wherein the compressor operates to dispense atomized disinfectant fluid continuously to bring the enclosed area to a target saturation level, and a pulse phase wherein the compressor operates to intermittently dispense atomized disinfectant fluid to maintain the enclosed area at the target saturation level.Type: GrantFiled: July 25, 2017Date of Patent: October 9, 2018Inventor: Steven T. Grinstead